HK2 and neoplasm: A dual novel EGFR/HER2 inhibitor, KU004, can inhibit the expression of hexokinase II (HK2) through PI3K/AKT signaling pathway, thereby inhibiting glycolysis and tumor growth (Tian et al., 2017).